CD30 Antibody [clone Ber-H2] (V2990S)

Catalog No.	Formulation	Size
V2990S-0.5ML	Bioreactor concentrate with 0.05% sodium azide	0.5 ml
V2990S-0.1ML	Bioreactor concentrate with 0.05% sodium azide	0.1 ml

Citations (12)

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human
Format	Culture supernatant
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	Ber-H2
Purity	Unpurified high titer supernatant
UniProt	P28908
Localization	Cell surface, cytoplasmic
Applications	Immunohistochemistry (FFPE) : 1:50-1:100 for 30 min at RT (1)
Limitations	This CD30 antibody is available for research use only.



IHC: Formalin-fixed, paraffin-embedded human Hodgkin's lymphoma stained with CD30 antibody (Ber-H2).

Description

CD30 antibody clone Ber-H2 is a monoclonal antibody that detects CD30, a member of the tumor necrosis factor receptor superfamily. CD30 is expressed on activated T and B cells, as well as in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma and in anaplastic large cell lymphoma. Its restricted expression pattern makes CD30 an important diagnostic marker in hematopathology. NSJ Bioreagents supplies this antibody for oncology, hematology, and immunology research.

The antibody produces strong membranous and Golgi-associated staining in CD30-positive cells. In diagnostic pathology, it is widely applied to confirm classical Hodgkin lymphoma and anaplastic large cell lymphoma. The antibody supports tumor classification and helps distinguish CD30-positive lymphomas from other hematologic malignancies.

In oncology, CD30 antibody clone Ber-H2 is applied to research into lymphoma pathogenesis, prognosis, and therapy. CD30 serves as the target of therapeutic antibodies such as brentuximab vedotin, and this reagent has been used to confirm antigen expression in translational and preclinical studies.

In immunology, CD30 plays a role in T cell activation, signaling, and apoptosis. The antibody has been applied to models of immune regulation, particularly in understanding the role of CD30 in regulating effector T cell populations.

In developmental hematology, CD30 expression has been studied in relation to lymphocyte activation and differentiation. Detection with this antibody continues to provide insight into immune responses beyond oncology.

Validated across tissue and cell-based systems, the antibody consistently delivers strong staining with minimal background. Alternate names include TNFRSF8 antibody, Hodgkin lymphoma marker antibody, and anaplastic large cell lymphoma marker antibody.

Application Notes

Optimal dilution of the CD30 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min.

Immunogen

A Co cell line established from a patient with Hodgkin s disease of T-cell lineage was used as the immunogen for the CD30 antibody.

Storage

Store the CD30 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).